Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Pulmonary alveolar proteinosis: from classification to therapy

Elena Salvaterra, Ilaria Campo
Breathe 2020 16: 200018; DOI: 10.1183/20734735.0018-2020
Elena Salvaterra
1Dept of Internal Medicine, University of Pavia, Pavia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elena Salvaterra
Ilaria Campo
2Pneumology Unit, IRCCS Policlinico San Matteo Hospital Foundation, Pavia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ilaria Campo
  • For correspondence: i.campo@smatteo.pv.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    PAP pathogenesis. In normal surfactant homeostasis (bottom right), surfactant is synthesised by type II alveolar epithelial cells and secreted into the alveolar space to generate a thin layer. GM-CSF is a cytokine produced by type II alveolar epithelial cells that binds specific receptors on macrophages; GM-CSF induces the terminal differentiation of alveolar macrophages, allowing an effective surfactant catabolism. In primary PAP (bottom left), altered macrophage activation, due to a dysfunction in GM-CSF signalling, leads to impaired surfactant clearance and to the consequent accumulation of surfactant. In autoimmune PAP, GM-CSF signalling is inhibited by the presence of neutralising GM-CSF autoantibodies; the hereditary form is the result of mutations involving the GM-CSF receptor. In secondary PAP (top left), various underlying conditions can affect the number and/or the function of the alveolar macrophages, causing reduced surfactant clearance and surfactant accumulation within the alveoli. In congenital PAP (top right), mutations in SFTPB, SFTPC, ABCA3 and TTF1 interfere with the production of surfactant which, in turn, is ineffective and prone to accumulation.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Chest HRCT findings in PAP. a) Interlobular septal thickening within interspersed ground glass (“crazy paving” pattern) is spread symmetrically to all five lobes with a perihilar predominance. b) After whole-lung lavage treatment, the crazy paving pattern is still appreciable but with reduced distribution and lower alveolar infiltration.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Diagnostic algorithm of PAP syndrome. PAP can be suspected based on a congruent clinical picture, compatible chest HRCT findings and an evocative BAL fluid. BAL fluid cytological analysis can confirm the diagnosis of PAP syndrome; subsequently, the diagnostic effort is directed to the identification of the specific PAP-causing disease. In the absence of a clear PAP-causing disease, GM-CSF autoantibody measurement should be performed to identify autoimmune PAP, the most frequent aetiology of PAP. Low levels of GM-CSF autoantibodies exclude the diagnosis of autoimmune PAP and dictate further investigations: accurate research of possible secondary PAP-causing disease, serum GM-CSF measurement and GM-CSF signalling test. High levels of serum GM-CSF indicate GM-CSF receptor dysfunction, highlighting hereditary PAP, which can be confirmed by the GM-CSF signalling test and specific gene analysis. Normal levels of serum GM-CSF and a GM-CSF signalling test within normality suggest the presence of congenital PAP that should be assessed with specific genetic tests [4]. LDH: lactate dehydrogenase.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    WLL schematic procedure. WLL is an invasive procedure almost universally performed under general anaesthesia, in an intensive care unit. In this example, the patient lies in the full lateral position; selective ventilation is assured by using a double-lumen endobronchial intubation. The lung above undergoes the lavage, while the other is selectively ventilated; an aliquot of warm saline is infused by gravity into the nonventilated lung and the collection tube is clamped. Subsequently, the aliquot is drained from the lavaged lung and received by gravity by the fluid collector. These passages are repeated until the collected fluid turns clears or until achievement of the programmed total infusion volume for each lung. Chest percussion can be associated during the procedure in order to emulsify the surfactant sediment.

Tables

  • Figures
  • Table 1

    Classification of PAP

    Primary PAP: GM-CSF signalling disruption
    • Autoimmune PAP (GM-CSF autoantibodies)

      Hereditary PAP (mutations in genes encoding GM-CSF receptor)

    Secondary PAP: reduction in function and/or number of alveolar macrophages
    • Haematological disorders

      Malignancies

      Immune deficiency syndromes

      Chronic inflammatory syndromes

      Chronic infections

      Toxic inhalation syndromes

      Other

    Congenital PAP: impaired surfactant production
    • Mutations in surfactant proteins (SFTPA, SFTPB, SFTPC)

      Mutations in lipid transporter (ABCA3)

      Mutations affecting lung development (TTF1)

    GM-CSF: granulocyte–macrophage colony-stimulating factor.

    • Table 2

      PAP clinical manifestations

      • No symptoms

      • 31.4%

      • Exertional dyspnoea

      • 39.0%

      • Cough

      • 9.9%

      • Dyspnoea and cough

      • 10.9%

      • Dyspnoea and sputum

      • 1.3%

      • Dyspnoea, cough and sputum

      • 2.2%

      • Other

      • 4.0%

    PreviousNext
    Back to top
    Vol 16 Issue 2 Table of Contents
    Breathe: 16 (2)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Pulmonary alveolar proteinosis: from classification to therapy
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Pulmonary alveolar proteinosis: from classification to therapy
    Elena Salvaterra, Ilaria Campo
    Breathe Jun 2020, 16 (2) 200018; DOI: 10.1183/20734735.0018-2020

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Pulmonary alveolar proteinosis: from classification to therapy
    Elena Salvaterra, Ilaria Campo
    Breathe Jun 2020, 16 (2) 200018; DOI: 10.1183/20734735.0018-2020
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • Abstract
      • Pulmonary alveolar proteinosis: a respiratory syndrome rather than a single disease
      • PAP: rare and rarest forms
      • The importance of pulmonary surfactant in all PAP forms: composition, function and homeostasis
      • When to suspect PAP: clinical, radiological and functional aspects
      • From clinical suspicion to PAP diagnosis, step by step
      • PAP clinical course
      • Different PAP forms, different therapies
      • Conclusions
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF

    Subjects

    • Interstitial and orphan lung disease
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Industry influence in healthcare harms patients: myth or maxim?
    • Venous thromboembolic disease in pregnancy
    • Diagnosis and management of NTM infection
    Show more Reviews

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About Breathe

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Intructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 1810-6838
    Online ISSN: 2073-4735

    Copyright © 2022 by the European Respiratory Society